摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

diallyl 4-{N-[4'-bis(2''-iodoethyl)aminophenyl]-N-methylcarbamoyloxymethyl}phenylcarbamoyl-L-glutamate | 528836-56-8

中文名称
——
中文别名
——
英文名称
diallyl 4-{N-[4'-bis(2''-iodoethyl)aminophenyl]-N-methylcarbamoyloxymethyl}phenylcarbamoyl-L-glutamate
英文别名
diallyl, 4-{N-[4'-bis(2"-iodoethyl) amino-phenyl]-N-methyl-carbamoyl-oxymethyl}-phenyl-carbamoyl-L-glutamate;bis(prop-2-enyl) (2S)-2-[[4-[[[4-[bis(2-iodoethyl)amino]phenyl]-methylcarbamoyl]oxymethyl]phenyl]carbamoylamino]pentanedioate
diallyl 4-{N-[4'-bis(2''-iodoethyl)aminophenyl]-N-methylcarbamoyloxymethyl}phenylcarbamoyl-L-glutamate化学式
CAS
528836-56-8
化学式
C31H38I2N4O7
mdl
——
分子量
832.474
InChiKey
GVBRPRCLFMKQCV-MHZLTWQESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.9
  • 重原子数:
    44
  • 可旋转键数:
    21
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    127
  • 氢给体数:
    2
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    diallyl 4-{N-[4'-bis(2''-iodoethyl)aminophenyl]-N-methylcarbamoyloxymethyl}phenylcarbamoyl-L-glutamate四氢吡咯四(三苯基膦)钯 作用下, 以 二氯甲烷 为溶剂, 以77.8%的产率得到4-{N-[4'-bis(2"-iodoethyl)amino-phenyl]-N-methyl-carbamoyl-oxymethyl}-phenyl-carbamoyl-L-glutamic acid
    参考文献:
    名称:
    Self-Immolative Nitrogen Mustards Prodrugs Cleavable by Carboxypeptidase G2 (CPG2) Showing Large Cytotoxicity Differentials in GDEPT
    摘要:
    Nineteen novel potential self-immolative prodrugs and their corresponding drugs have been synthesized for gene-directed enzyme prodrug therapy (GDEPT) with carboxypeptidase G2 (CPG2) as the activating enzyme. The compounds are derived from o- and p-amino and p-methylamino aniline nitrogen mustards. Their aqueous stability, kinetics of drug release by CPG2, and cytotoxicity in the colon carcinoma cell line WiDr, expressing either surface-tethered CPG2 (stCPG2(Q)3) or control beta-galactosidase, are assessed. The effect of various structural features on stability, kinetics of activation, and biological activity is discussed. The p-methylamino prodrugs are the most stable compounds from this series, with the largest cytotoxicity differentials between CPG2-expressing and nonexpressing cells. The most potent compounds in all series are prodrugs of bis-iodo nitrogen mustards. 4-{N-[4'-Bis(2"-iodoethyl)aminophenyll-N'-methylcarbamoyloxymethyl}phenylcarbamoyl-L-glutamic acid, compound 39b, is 124-fold more cytotoxic to WiDr cells expressing CPG2 than to cells expressing beta-galactosidase. An additional six compounds show better cytotoxicity differential than the published N-{4-[(2-chloroethyl)(2-mesyloxyethyl)amino]benzoyl}-L-glutamic acid (CMDA) prodrug.
    DOI:
    10.1021/jm020462i
  • 作为产物:
    描述:
    N-(4-硝基苯基)二乙醇胺 在 palladium on activated charcoal 咪唑4-二甲氨基吡啶 、 triethylamine trihydrofluoride 、 氢气 、 sodium hydride 、 三乙胺 、 sodium iodide 作用下, 以 四氢呋喃二氯甲烷N,N-二甲基乙酰胺乙酸乙酯N,N-二甲基甲酰胺丙酮 为溶剂, 反应 177.67h, 生成 diallyl 4-{N-[4'-bis(2''-iodoethyl)aminophenyl]-N-methylcarbamoyloxymethyl}phenylcarbamoyl-L-glutamate
    参考文献:
    名称:
    Self-Immolative Nitrogen Mustards Prodrugs Cleavable by Carboxypeptidase G2 (CPG2) Showing Large Cytotoxicity Differentials in GDEPT
    摘要:
    Nineteen novel potential self-immolative prodrugs and their corresponding drugs have been synthesized for gene-directed enzyme prodrug therapy (GDEPT) with carboxypeptidase G2 (CPG2) as the activating enzyme. The compounds are derived from o- and p-amino and p-methylamino aniline nitrogen mustards. Their aqueous stability, kinetics of drug release by CPG2, and cytotoxicity in the colon carcinoma cell line WiDr, expressing either surface-tethered CPG2 (stCPG2(Q)3) or control beta-galactosidase, are assessed. The effect of various structural features on stability, kinetics of activation, and biological activity is discussed. The p-methylamino prodrugs are the most stable compounds from this series, with the largest cytotoxicity differentials between CPG2-expressing and nonexpressing cells. The most potent compounds in all series are prodrugs of bis-iodo nitrogen mustards. 4-{N-[4'-Bis(2"-iodoethyl)aminophenyll-N'-methylcarbamoyloxymethyl}phenylcarbamoyl-L-glutamic acid, compound 39b, is 124-fold more cytotoxic to WiDr cells expressing CPG2 than to cells expressing beta-galactosidase. An additional six compounds show better cytotoxicity differential than the published N-{4-[(2-chloroethyl)(2-mesyloxyethyl)amino]benzoyl}-L-glutamic acid (CMDA) prodrug.
    DOI:
    10.1021/jm020462i
点击查看最新优质反应信息

文献信息

  • [EN] ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS<br/>[FR] PROMEDICAMENTS ACTIVES PAR UNE ENZYME ET AUTO-IMMOLATEURS A BASE DE MOUTARDE D'AZOTE N-SUBSTITUTE
    申请人:CANCER REC TECH LTD
    公开号:WO2004020400A1
    公开(公告)日:2004-03-11
    This invention pertains to certain enzyme (CPG2) activated self-immolative nitrogen mustard prodrugs, which are useful in enzyme prodrug therapy (EPT), such as ADEPT and GDEPT, for the treatment of proliferative conditions, such as cancer, and which have the following formula: wherein RN is independently C1-7alkyl; X1 is independently -I, -Br, or Cl; X2 is independently -I, -Br, or -Cl; the group -N(CH2CH2X1)(CH2CH2X2) is independently attached at the 2-position or at the 4-position; each RG is independently -H or an ester substituent; n is independently an integer from 0 to 4; each RP, if present, is independently a phenyl substituent; m is independently an integer from 0 to 4; each RM, if present, is independently a mustard substituent; and pharmaceutically acceptable salts, solvates, amides, and esters thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds; such compounds and compositions for use in methods of treatment of the human or animal body by therapy; the use of such compounds and compositions for the manufacture of medicaments for the treatment of proliferative conditions; and the like.
    本发明涉及一种特定的酶(CPG2)活化的自灭性亚硝基芥子前药,用于酶前药疗法(EPT),如ADEPT和GDEPT,用于治疗增殖性疾病,如癌症,并具有以下结构式:其中RN独立地是C1-7烷基;X1独立地是-I,-Br或Cl;X2独立地是-I,-Br或-Cl;该基团-N(CH2CH2X1)(CH2CH2X2)独立地连接在2位或4位;每个RG独立地是-H或酯基取代物;n独立地是0到4的整数;每个RP(如果存在)独立地是苯基取代物;m独立地是0到4的整数;每个RM(如果存在)独立地是芥子取代物;以及其药学上可接受的盐、溶剂化合物、酰胺和酯。本发明还涉及包含这种化合物的药物组合物;这种化合物和组合物用于通过治疗治疗人体或动物体的方法;这种化合物和组合物用于制造用于治疗增殖性疾病的药物;等等。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸